Angiogenesis is essential for tumor growth and inhibiting angiogenesis has become an important therapeutic strategy in clinical
oncology. Nonetheless, the mechanisms behind anti-angiogenic therapeutics as well as resistance to these drugs remain unclear. With
a lack of validated genetic or molecular biomarkers for anti-angiogenic responsiveness, novel methods to identify responsive patients are
required. Non-invasive nuclear imaging would allow the elucidation of the basic drug mechanisms as well as resistance routes and aid the
personalization of anti-angiogenic therapy by enabling target expression quantification prior to and during treatment. This review focuses
on the development of radiolabeled probes to image four key proteins expressed during angiogenesis, namely vascular endothelial growth
factor and its receptor, integrin αv β3, the extracellular domain of fibronectin and matrix metalloproteases, and how these probes can be
utilized for personalized anti-angiogenic therapy.
Keywords: Angiogenesis, radiolabeled imaging probes, personalized medicine, integrin αv β3, VEGF, RGD.
Rights & PermissionsPrintExport